Allergy Therapeutics PLC (AIM:AGY) (LON:AGY) Head of Business Innovation Alan Bullimore caught up with Proactive London to talk about the results from a study targeting grass pollen allergies.
The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.
As he explains there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks.